JUBLPHARMA IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| JUBLINGREAJubilant Ingrevia Ltd. | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “Transfer in of vendor related liabilities: Jubilant Pharmova Limited - 5.62 - - - 5.62 - 5.62 - - - 5.62 20.” AR DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| DIXONDixon Technologies (India) Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “He is currently serving as an independent director on the board of companies like, Jubilant Pharmova Ltd, Jubilant Ingrevia Ltd. Also, he is in the Board of Ke…” AR · +1 DOC | ||||||||
| MEDANTAGlobal Health Ltd. | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “He currently serves as co-chairman and managing director at Jubilant Pharmova Limited.” AR DOC | ||||||||
| JUBLINGREAJubilant Ingrevia Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Trade payables: Jubilant Infrastructure Limited 142.43 - - - - 142.43 Jubilant Agro Sciences Limited 2.90 - - - - 2.90 Jubilant Lifesciences NV 3.60 - - - - 3.…” AR · +1 DOC | ||||||||
| JUBLINGREAJubilant Ingrevia Ltd. | UNSTATED | — | — | — | SG&A | FY26 | EST | 70% |
| “Note 49: Detail of immovable properties where title deed is not held in the name of the Company is as follows: The title/lease deeds of all the immovable prope…” AR · +1 DOC | ||||||||
No order filings, annual reports, concalls or rating rationales are linked to JUBLPHARMA.
relationship sources are linked on ingest| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | -6.2% | 16-NOV-26 | from 17-OCT-26 · Jubilant Ingrevia Ltd. -6.2% |
| SUPP MOM 1M | +4.9% | 16-NOV-26 | from 17-OCT-26 · Dixon Technologies (India) Ltd. +3.7% w 0 · Global Health Ltd. +17.3% w 0 · Jubilant Ingrevia Ltd. -6.2% w 0 |